METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT

(19)

(11)

EP 3 881 680 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	26.02.2025 Bulletin 2025/09

(45)	Mention of the grant of the patent:
	15.01.2025 Bulletin 2025/03

(21)	Application number: 21157228.4

(22)	Date of filing: 30.10.2015

(51)

International Patent Classification (IPC):

A01N 63/00^(2020.01)
A61K 31/733^(2006.01)
A61K 45/06^(2006.01)
A61K 35/741^(2015.01)
A61P 3/00^(2006.01)
A61P 3/10^(2006.01)

C12N 1/20^(2006.01)
A61K 35/74^(2015.01)
A23L 33/135^(2016.01)
A61K 35/00^(2006.01)
A61P 3/04^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 35/74; C12N 1/20; A61K 45/06; G01N 2333/605; G01N 2800/04; A23L 33/135; A23V 2002/00; A61K 31/733; A61K 35/741; A61K 2035/115; A61P 3/00; A61P 3/04; A61P 3/10

	C-Sets:
	A61K 31/733, A61K 2300/00; A23V 2002/00, A23V 2200/3202, A23V 2200/3204, A23V 2200/328, A23V 2200/332;

(54)	METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT VERFAHREN UND ZUSAMMENSETZUNGEN IM ZUSAMMENHANG MIT MIKROBIELLER BEHANDLUNG VON STÖRUNGEN PROCÉDÉS ET COMPOSITIONS SE RAPPORTANT À UN TRAITEMENT MICROBIEN DE TROUBLES

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

31.10.2014 US 201462073912 P

(43)	Date of publication of application:
	22.09.2021 Bulletin 2021/38

(60)	Divisional application:
	24218291.3

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	15853671.4 / 3212001

(73)	Proprietor: Pendulum Therapeutics, Inc.
	San Francisco, CA 94107 (US)

(72)	Inventors:
	CUTCLIFFE, Colleen Menlo Park, CA California 94025 (US) EID, John S. San Francisco, CA California 94110 (US) BULLARD, James H. San Francisco, CA California 94107 (US) SCHICKLBERGER, Marcus F. Richmond, CA California 94804 (US)

(74)	Representative: Avidity IP
	Broers Building Hauser Forum 21 JJ Thomson Avenue Cambridge CB3 0FA Cambridge CB3 0FA (GB)

(56)

References cited: :

WO-A1-2014/011233
WO-A2-2014/145958
US-A- 5 143 845
US-A1- 2009 010 892

WO-A1-2014/152338
JP-A- 2007 031 291
US-A1- 2009 010 891
US-A1- 2013 224 155

MEKKES M C ET AL: "The development of probiotic treatment in obesity: a review", BENEFICIAL MICR, WAGENINGEN ACADEMIC PUBLISHERS, NL, vol. 5, no. 1, 1 March 2014 (2014-03-01), pages 19 - 28, XP009181740, ISSN: 1876-2883, DOI: 10.3920/BM2012.0069
FALONY G ET AL: "Cross-feeding between Bifidobacterium longum BB536 and acetate-converting, butyrate-producing colon bacteria during growth on oligofructose", APPLIED AND ENVIRONMENTAL MICROBIOLOGY DECEMBER 2006 AMERICAN SOCIETY FOR MICROBIOLOGY US, vol. 72, no. 12, December 2006 (2006-12-01), pages 7835 - 7841, XP028249378, DOI: 10.1128/AEM.01296-06
DATABASE GNPD [online] MINTEL; February 2015 (2015-02-01), PHARMXCROSS: "Triple Premium Alive Probiotics", XP002779023, Database accession no. 2898253
PETRA LOUIS ET AL: "Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine", FEMS MICROBIOLOGY LETTERS, vol. 294, no. 1, 1 May 2009 (2009-05-01), pages 1 - 8, XP055397860, ISSN: 0378-1097, DOI: 10.1111/j.1574-6968.2009.01514.x
M. VITAL ET AL: "Revealing the Bacterial Butyrate Synthesis Pathways by Analyzing (Meta)genomic Data", MBIO, vol. 5, no. 2, 22 April 2014 (2014-04-22), US, pages 1 - 11, XP055195014, ISSN: 2150-7511, DOI: 10.1128/mBio.00889-14
ALESSANDRA PUDDU ET AL: "Evidence for the Gut Microbiota Short-Chain Fatty Acids as Key Pathophysiological Molecules Improving Diabetes", MEDIATORS OF INFLAMMATION., vol. 2014, 1 January 2014 (2014-01-01), GB, pages 1 - 9, XP055397861, ISSN: 0962-9351, DOI: 10.1155/2014/162021


	Remarks:
	The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).